Avalanche Biotechnologies, Inc. Reports First Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Avalanche Biotechnologies (AAVL) Misses Q1 EPS by 18c
May 6, 2016 7:15 AM EDTAvalanche Biotechnologies (NASDAQ: AAVL) reported Q1 EPS of ($0.57), $0.18 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $265 thousand versus the consensus estimate of $400 thousand.
For earnings history and earnings-related data on Avalanche Biotechnologies (AAVL) click here.
... More